3. Okazaki T, Honjo T.PD-1 and PD-1 ligands:from discovery to clinical application.Int Immunol, 2007, 19:813-824.
[4]
9. Zhang Y, Li J, Lou J, et, al.Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients.Crit Care, 2011, 15:R70.
[5]
10. Guignant C, Lepape A, Huang X, et al.Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients.Crit Care, 2011, 15:R99.
[6]
11. Rittirsch D, Huber-Lang MS, Flierl MA, et al.Immunodesign of experimental sepsis by cecal ligation and puncture.Nat Protoc, 2009, 4:31-36.
[7]
12. Singleton KD, Wischmeyer PE.Distance of cecum ligated influences mortality, tumor necrosis factor-alpha and interleukin-6 expression following cecal ligation and puncture in the rat.Eur Surg Res, 2003, 35:486-491.
5. Powles T, Eder JP, Fine GD, et al.MPDL3280A(anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.Nature, 2014, 515:558-562.
[10]
6. Said EA, Dupuy FP, Trautmann L, et al.Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.Nat Med, 2010, 16:452-459.
[11]
7. Huang X, Chen Y, Chung CS, et al.Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis.J Immunol, 2014, 192:1091-1099.
